Pure Global
NCT06155019

Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination

Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination in Virologically Suppressed People Living With HIV (PLWH): the French Multicenter, Observational SWEED Study
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
HIV Infections
Study type
Observational
Sponsor & location
Primary sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Timeline & enrollment
Phase
N/A
Start date
Dec 15, 2023
End date
Jun 15, 2024
Enrollment
120 participants
Primary outcome

Measure the virological efficacy at week 48 a doravirine-containing ART to assess the effectiveness of the switch to maintain the virological success to W48

Summary

The main objective of the SWEED study is to determine whether doravirine containing ART is
 able to maintain viral suppression at W48 in HIV-1 infected people living with HIV (PLWH)
 receiving etravirine containing ART:
 
 - An ARV strategy containing doravirine as a replacement for etravirine can maintain
 virological suppression in participants with controlled viral replication under ARV
 treatment containing etravirine, with a virological success rate 90%
 
 - This strategy can maintain virological suppression even in the event of NNRTI resistance
 mutations acquired in the past
 
 - This strategy is well tolerated
 
 - The emergence of resistance to NNRTIs is uncommon in the event of virological failure
 under the ARV regimen containing doravirine

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155019
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06155019 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.